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INTRODUCTION 
 
Tonsillectomy is one of the commonest surgical procedures performed 
in the field of otorhinolaryngology. The most common and distressing 
symptoms, which follow anaesthesia and surgery, are pain and emesis1. The 
provision of adequate analgesia after tonsillectomy presents the 
anaesthesiologist with difficulties, as this is a painful procedure and may be 
associated with significant bleeding into the airway2. As evidence continues to 
accumulate concerning the role of central sensitisation in post operative pain, 
many researchers have followed methods to prevent central neuropathic 
changes from occurring, through the utilization of pre-emptive analgesic 
techniques. Effective preventive analgesic technique may not only be useful in 
reducing the acute pain, but also chronic post surgical pain and disabilities. 
Paracetamol is an effective analgesic and an antipyretic agent3, 4. The 
efficiency and tolerability for intravenous Paracetamol are well established. It 
has a favourable safety profile and it is the most commonly prescribed drug 
for the treatment of mild to moderate pain. The objective of the present study 
is to evaluate the post operative analgesia, the haemodynamic profile and the 
side effects of IV Paracetamol. 
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AIM OF THE STUDY  
 
• To evaluate the efficacy of Intravenous Paracetamol as a pre-emptive 
analgesic in relieving the post operative pain. 
• To study the hemodynamic variables during the post-operative period. 
• To establish the safety of Intravenous paracetamol in patients. 
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REVIEW OF LITERATURE 
 
Atef A et al5 performed a prospective placebo-controlled study to 
evaluate the analgesic efficacy and safety of intravenous paracetamol 
undergoing elective standard bipolar diathermy tonsillectomy and concluded 
that intravenous paracetamol significantly reduced pethidine consumption 
over a 24 hour period. The worst pain after surgery was also more severe in 
the placebo group than that in the paracetamol group. There was no 
significant difference between groups in the incidence of adverse events. 
Intravenous paracetamol administered regularly in adult patients with 
moderate to severe pain after tonsillectomy provided rapid and effective 
analgesia and was well tolerated. 
 
Alhashemi JA et al6 compared i.v. acetaminophen with intramuscular 
(i.m.) meperidine with regard to analgesic effects in paediatric patients 
undergoing tonsillectomy. They concluded that compared with i.m. 
meperidine, i.v. acetaminophen provided adequate analgesia, less sedation 
and earlier readiness for recovery room discharge among paediatric patients 
undergoing tonsillectomy. 
 
Alhashemi JA et al7, in another study, compared i.v. acetaminophen 
with intramuscular (i.m.) meperidine with regard to postoperative analgesia 
and readiness for discharge in paediatric patients undergoing day care dental 
restoration. They concluded that compared with i.m. meperidine, 
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intraoperative i.v. acetaminophen resulted in slightly higher pain scores but 
earlier readiness for recovery room discharge in paediatric patients 
undergoing dental restoration. 
 
Oscier et al8 reviewed the peri-operative use of paracetamol. It 
reviews the pharmacology of paracetamol, highlighting new information about 
the mechanism of action, and examines its therapeutic use in the peri-
operative period, focusing on efficacy, route of administration, and the use of 
a loading dose to improve early postoperative analgesia. 
 
Sinatra RS et al9 conducted a repeated-dose, randomized, double-
blind, placebo-controlled, three-parallel group study to evaluate the analgesic 
efficacy and safety of intravenous acetaminophen as compared with its pro-
drug Propacetamol. They concluded that intravenous acetaminophen 1g, 
administered over a 24-h period in patients with moderate to severe pain after 
orthopedic surgery provided rapid and effective analgesia and was well 
tolerated. 
 
C Remy, E Marret, F Bonnet, et al10 in their study analyzed the effect 
of paracetamol on morphine side-effects and consumption after major surgery 
and concluded that paracetamol combined with PCA induced a significant 
morphine sparing effect.  
 
Ahmed AI Fadly et al11 studied the analgesic effect of intravenous 
paracetamol, morphine and their combination for post operative pain after 
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release of post burn neck contractures and concluded that iv paracetamol 
effectively reduces morphine requirements by 60% or even replace it with less 
incidence of adverse events and more safer course during postoperative pain 
management after release of post burn neck contracture in adults. 
 
Murat-et al12 evaluated the relative analgesic efficacy of paracetamol 
with propacetamol for 6 hours after inguinal hernia repair under GA with 
ilioinguinal block in children. They concluded that a single infusion of iv 
paracetamol 15 mg/kg provides analgesia similar to single infusion of 
propacetamol 30 mg/kg following inguinal hernia repair in children. 
 
Iolter Cattabriga et al13 Studied the efficacy of intravenous 
paracetamol as an adjunctive analgesic to a tramadol-based background 
analgesia after cardiac surgery and concluded that in patients undergoing 
cardiac surgery, intravenous paracetamol in combination with tramadol 
provides effective pain control.  
 
Zaka Ullah khan et al 14conducted a prospective randomized study 
comparing the analgesic effect of intravenous Paracetamol with intravenous 
Morphine in postoperative pain control of patients undergoing knee 
arthroscopic surgery as day cases and concluded that both intravenous 
Paracetamol and intravenous Morphine seems to have the same analgesic 
effect. However, side effects with intravenous Paracetamol were much less. 
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Mehmet Turan Inal et al15 compared the quality of analgesia and side 
effects of iv paracetamol versus meperidine for postoperative analgesia after 
elective caesarean section and concluded that i.v. paracetamol has better 
analgesic potency than i.v. meperidine for postoperative analgesia after 
caesarean section. 
 
Duggan et al16 reviewed all studies conducted with i.v. paracetamol 
and concluded that  intravenous paracetamol has better analgesic effficacy in 
relieving pos operative pain and well tolerated.  
 
16 
 
PATHOPHYSIOLOGY OF PAIN 
 
Introduction 
Pain is a personal, subjective experience that involves sensory, 
emotional and behavioural factors associated with actual or potential tissue 
injury. What patients tell us about their pain can be very revealing, and an 
understanding of how the nervous system responds and adapts to pain in the 
short and long term is essential if we are to make sense of patients’ 
experiences. The wide area of discomfort surrounding a wound, or even a 
wound that has healed long ago, such as an amputation stump, is a natural 
consequence of the plasticity of the nervous system. An understanding of the 
physiological basis of pain is helpful to the sufferer, and the professionals who 
have to provide appropriate treatment. It must be stated at the outset that in 
humans pain is invariably associated with pain behaviour and pain generally 
results in some degree of suffering. Nociception, neuropathy or psychological 
and environmental factors may singly, or in combination, result in pain.  
 
Definition of pain 
The definition of pain promulgated by the International Association for 
the Study of Pain is very appropriate:”Pain is defined as an unpleasant 
sensory or emotional experience associated with actual or potential tissue 
damage or described in terms of such damage”. 
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There is individual variation in response to pain, which is influenced by 
genetic makeup, cultural background, age and gender. Certain patient 
populations are at risk of inadequate pain control and require special 
attention. These include: 
 
• Paediatric patients 
• Geriatric patients 
• Patients with difficulty in communicating (due to critical illness, 
cognitive impairment or language barriers)  
 
Postoperative pain can be divided into acute pain and chronic pain: 
• Acute pain is experienced immediately after surgery (up to 7 days) 
• Pain which lasts more than 3 months after the injury is considered to 
           be chronic pain  
 
  Acute and chronic pain can arise from cutaneous, deep somatic or 
visceral structures. Surgery is typically followed by acute pain and correct 
identification of the type of pain enables selection of appropriate effective 
treatment. The type of pain may be somatic (arising from skin, muscle, bone), 
visceral (arising from organs within the chest and abdomen), or neuropathic 
(caused by damage or dysfunction in the nervous system). Patients often 
experience more than one type of pain. 
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Positive role of pain 
Acute pain plays a useful "positive" physiological role by: 
 Providing a warning of tissue damage 
 Inducing immobilisation to allow appropriate healing 
Negative effects of pain 
Short term negative effects of acute pain include: 
 Emotional and physical suffering for the patient 
 Sleep disturbance (with negative impact on mood and mobilisation) 
 Cardiovascular side effects (such as hypertension and tachycardia) 
 Increased oxygen consumption(with negative impact in the case of 
coronary artery disease) 
 Impaired bowel movement (while opioids induce constipation or 
nausea, untreated  pain may also be an important cause of impaired 
bowel movement or post operative nausea and vomitting) 
 Negative effects on respiratory function (leading to atelectasis, 
retention of secretions and pneumonia) 
 
Long term negative effects of acute pain: 
 Severe acute pain is a risk factor for the development of chronic pain 
 There is a risk of behavioural changes in children for a prolonged 
period (up to 1  year) after surgical pain 
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There are two major mechanisms in the physiology of pain: 
 Nociceptive (sensory): Inflammatory pain due to chemical, 
mechanical and thermal stimuli at the nociceptors (nerves that respond 
to      painful stimuli). 
 Neuropathic: Pain due to neural damage in peripheral nerves or within 
the central nervous system. 
 
Pain is a complex phenomenon and includes both  
 Sensory – discriminative and  
 Motivational – affective components 
 
Sensory –discriminative component:   
This component depends upon the ascending projection of tracts like 
spinothalamic and trigeminothalamic tracts into the cerebral cortex.  Thus they 
help to perceive the quality of pain that is pricking, burning quality etc. They 
also help to know the location of stimulus, intensity and duration of the 
stimulus. 
 
Motivational - affective component:  
 It includes attention, arousal, somatic, autonomic reflexes, endocrine 
and emotional changes. These collectively contribute to the unpleasant nature 
of pain. 
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Qualitatively there are two types of pain  
1. Fast pain - is short, well localized, stabbing sensation that is matched to 
the stimulus like in pin prick, surgical incision. This pain starts abruptly 
when the stimulus is applied and stops when the stimulus is removed. This 
is due to stimulation of small myelinated Aδ fibers with conduction 
velocities of 12 to 30 m/s.  Myelination provides junctions that permit the 
electrical impulses to jump which results in rapid transmission.  
2. Slow pain- is throbbing, burning or aching sensation that is poorly 
localized and poorly matched to stimulus. This is due to stimulation of 
unmyelinated C -fibers with conduction velocity of 0.5 to 2 m/s. 
 
Pain receptors: (Nociceptors)   
These are the free nerve endings present in the skin, muscles, joints, 
viscera, and in the vasculature.  These receptors detect the noxious stimulus 
due to the chemical, thermal (heat, cold) and mechanical changes.  In normal 
tissues they are inactive and are stimulated by a sufficient energy to 
overcome their resting threshold.  Thus they prevent random signal 
propagation to central nervous system for interpretation of pain. This is so 
called screening function.  The nociceptive neurons synapse in the dorsal 
horn of the spinal cord with both local interneurons and projection neurons 
that carry the nociceptive information to the higher centres present in the 
brainstem, thalamus.  In contrast to other sensory receptors “ the pain 
receptors do not adapt “ and this unique feature is protective and thus allows 
the individual be aware of continued tissue damage.  After damage, pain is 
usually minimal and also the onset pain depends upon the rate of metabolism, 
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e.g. ischemic injury of the skin usually produces pain with 20 to 30 minutes, 
but for the exercising muscles the pain occurs within 15 to 20 seconds. 
Certain specific types of nociceptors react only to the specific stimuli, but 
other nociceptors react to multiple stimuli for e.g. “C “ nociceptors and  A delta 
nociceptors react to heat or cold stimuli.  Some Aβ receptors which are 
usually mechanoreceptors may have nociceptor like activity. Aβ 
mechanoreceptor sensory fibres can be recruited to transmit signals that 
interpret as painful stimuli. But it occurs only when these receptors are in the 
environment of inflammation. The mechanical allodynia (painful sensation 
results from light touch) results from Aβ receptors recruitment. 
 
Wind-up phenomenon: 
 The temporal summation of number and duration of action potentials 
elicited per stimulus that occurs in the dorsal horn neurons has been referred 
to as wind-up phenomenon.  This result in persistence of action potential for 
up to sixty seconds after stopping the stimulus and results in change in spinal 
cord processing that can lasts for one to three hours. Spinal cord synaptic 
plasticity involves binding of glutamate to NMDA receptors as well as 
substance P and neurokinins. Binding of glutamate to NMDA receptors alters 
magnesium dependent block of ion channels, which increases permeability to 
all cations particularly Na+, Ca2+, furthermore glutamate activates AMPA 
receptors which  control depolarization primarily through modulation of  Na+ 
influx into cells. In addition to modulating augmented excitability these 
transmitters, cellular mechanism mediate changes in postsynaptic cells 
leading to permanent changes in nerve conduction.  It also plays a role in the 
22 
 
development of central sensitisation and intravenous paracetamol inhibits 
this phenomenon. 
 
Transmission and modulation: 
 Dorsal horn and its laminae act as receiving site for action potential 
coming from periphery via primary afferent neurons.  The primary afferents 
terminates in the dorsal horn and synapse with secondary afferent neurons. 
The secondary afferent neurons act as gate cells providing initial modulation 
of action potentials in the dorsal horn. Two main classes of neuro-transmitters 
associated with primary afferent nociceptive transmission in the dorsal horn 
1. Excitatory amino acids e.g., Glutamate  
2. Neurokinin  peptides eg., Substance P  
 
Perception: 
Thalamus and cortex:  
 After leaving the dorsal horn nociceptive action potentials ascends 
through  spinothalamic tract , spinocervical tracts ,Spino reticular tracts and 
spino mesencephalic tracts and reach higher centers like cerebral cortex , 
hypothalamus reticular formation and mid brain. Afferent impulses go to 
reticular area and activate this area which then sends signals through 
thalamus and cerebral cortex.  This alerts the individual to continuous tissue 
damage and awakens the person from sleep.  These signals are poorly 
localized and help to alert the individual.  
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NMDA receptors: 
 NMDA receptors are postsynaptic to primary afferent neuron and 
located on secondary afferent neurons.  They are blocked by Mg2+ ions. 
Under normal conditions, the secondary afferent neurons are not depolarized 
along enough to dislodge the Mg2+ ions from the ion channels to permit Ca2+ 
ions. Glutamate is rapidly removed from the synaptic cleft and there is no 
activity at NMDA receptors in normal nociceptive transmission.  But in the 
presence of pain arising from abnormal conditions like neuropathic pain, 
chronic pain, peripheral sensitization, the frequency of pain signals increases 
which in turn increases the amount of glutamate.  This glutamate depolarizes 
the secondary afferent neuron long enough to dislodge the Mg2+ which is 
blocking the NMDA receptors. Subsequent activation of NMDA receptors acts 
to activate second messengers, enzyme systems and various substances like 
nitric oxide that contributes to enhanced sensitivity known as central 
sensitization. The activation of NMDA by glutamate also activates protein 
kinase-C, which causes uncoupling of opioid receptors system results in 
decreasing responsiveness which is called opioid tolerance. Intravenous 
paracetamol inhibits these receptors also. 
 
Role of sensitisation mechanisms in treatment of pain18 
It is now recognised that a prolonged insult to the body produces 
changes in the nervous system which alter the "normal", "physiological" 
response to a noxious stimulus. As a result of the recognition of these 
changes, it has been proposed that pain be divided into two entities: 
"physiological" and "pathophysiological" or "clinical". The processes which 
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underlie our "physiological" experience of a noxious stimulus are quite 
different from the "pathophysiological" processes which occur in the clinical 
situation and which confront the practising clinician. Physiological pain 
describes the situation in which a noxious stimulus activates peripheral 
nociceptors, which then transmit that information through several relays, until 
it reaches the brain and is recognised as a potentially harmful stimulus. More 
commonly the insult to the body which produces pain also results in 
inflammation and nerve injury. The factors responsible for the development of 
"clinical" pain will result in a stimulus-response system that has quite different 
characteristics from those of "physiological" pain. Inflammation and nerve 
damage give rise to changes in sensory processing at a peripheral and 
central level with a resultant sensitisation. Once sensitisation has 
occurred, stimuli which normally would not produce pain are perceived as 
painful (allodynia) and there is an exaggerated response to painful stimuli 
(hyperalgesia). In particular, surgery produces a biphasic insult on the human 
body which has implications for pain management. Firstly, during surgery 
there is trauma to tissue, which produces a barrage of nociceptive input. 
Secondly, after surgery there is an inflammatory response at the site of injury 
which is also responsible for the generation of noxious input. Both of these 
processes, which occur during and after surgery, result in sensitisation of pain 
pathways. This occurs at a peripheral level where there is a reduction in the 
threshold of nociceptor afferents and at a central level with an increase in 
excitability of spinal neurons involved in pain transmission. This sensitisation 
has now been characterised. It has profound implications for the management 
of acute pain and has provoked interest in the use of pre-emptive analgesia 
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and new methods of postoperative pain management with new agents of non-
opioid type, possibly combined with opioid drugs. 
 
Central sensitization 17,18,19 
 The responses in the CNS are primarily physiological. Following injury, 
there is also an increased responsiveness to normally innocuous mechanical 
stimuli (allodynia) and a zone of secondary hyperalgesia in uninjured tissue 
surrounding the site of injury. These changes are believed to be a result of 
processes that occur in the dorsal horn of the spinal cord following injury. This 
is the phenomenon of central sensitisation. These changes indicate that, in 
the presence of pain, the central nervous system is not "hard-wired" but 
plastic, and the attempts to modify pain must take into account these 
changes. A barrage of nociceptive input, such as which occur with surgery, 
results in changes to the response properties of dorsal horn neurons. It has 
been demonstrated that a painful stimulus, which is at a level sufficient to 
activate C fibres, does not only activate dorsal horn neurons. It can also be 
observed that neuronal activity progressively increases throughout the 
duration of the stimulus. Therefore, with nociceptive input there is not a simple 
stimulus-response relationship but a "wind-up" of spinal cord neuron activity. 
This "wind-up" may make these neurons more sensitive to other input and is a 
component of central sensitisation. This finding has had a profound influence 
on concepts of pain and it is now known that a sustained C-fibre barrage in 
primary afferent fibres leads to other morphological and biochemical changes 
in the dorsal horn which may be difficult to reverse. Several other changes 
have been noted to occur in the dorsal horn with central sensitisation. Firstly, 
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there is an expansion in receptive field size so that a spinal neuron will 
respond to stimuli that would normally be outside the region which responds 
to nociceptive stimuli. Secondly, there is an increase in the magnitude and 
duration of the response to stimuli which are above threshold in strength. 
Lastly there is a reduction in threshold so that stimuli which are not normally 
noxious activate neurons which usually transmit nociceptive information. 
These changes may be important both in acute pain states, such as 
postoperative pain, and in the development of chronic pain. They manifest by 
the presence of hyperalgesia, allodynia and an increase in the size of the area 
of tenderness around a wound or injury. Nerve injury also results in changes 
in the dorsal horn. It has been demonstrated that following peripheral nerve 
injury the terminals of myelinated afferents sprout in neighbouring regions of 
the dorsal horn. This means that nerves which do not usually transmit pain 
sprout into a more superficial region of the dorsal horn that normally acts as a 
relay in pain transmission. If functional contact is made between these 
terminals which normally transmit non-noxious information and neurons that 
normally receive nociceptive input, this may provide a framework for the pain 
and hypersensitivity to light touch that is seen following nerve injury. 
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Central sentisation20 
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Peripheral sensitisation 
Several different types of stimuli can result in activation of the 
peripheral nociceptive pathway which ultimately results in the perception of 
pain. Under normal conditions, thermal, mechanical and chemical stimuli 
activate high threshold nociceptors which signal this information to the first 
relay in the dorsal horn. However, under clinical conditions application of a 
noxious stimulus is usually prolonged and traumatic and associated with 
tissue damage. Tissue damage results in an inflammatory response which 
directly affects pain sensation. Part of the inflammatory response is release of 
intracellular contents from damaged cells and inflammatory cells such as mast 
cells, macrophages and lymphocytes. Nociceptive stimulation also results in a 
neurogenic inflammatory response. This produces vasodilatation and 
extravasation of plasma proteins, as well as action on inflammatory cells to 
release chemical mediators. These interactions result in the release of a 
"soup" of inflammatory mediators such as potassium, serotonin, bradykinin, 
substance P, histamine and products from the cyclooxygenase and 
lipoxygenase pathways of arachidonic acid metabolism. These chemicals 
then act to sensitise high threshold nociceptors. Following sensitisation, low 
intensity stimuli which would not normally cause pain are now perceived as 
painful. This series of events which follows tissue injury is termed peripheral 
sensitisation. It is characterised by an increased responsiveness to thermal 
stimuli at the site of injury. If attempts are to be made to reduce the 
phenomenon of peripheral sensitisation, then efforts need to be focused on 
preventing or reducing the action of chemical mediators in the inflammatory 
"soup". This is the rationale for the current use of nonsteroidal anti-
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inflammatory drugs (NSAIDs) and in the future for use of other peripherally 
administered drugs such as conventional opioids, "peripherally acting" 
opioids, local anaesthetics (conventional and long acting) and so on. 
Inflammation also appears to have another important effect on peripheral 
nerves. It has been found that there is a class of unmyelinated primary 
afferent fibres that do not normally respond to excessive mechanical or 
thermal stimuli. However, in the presence of inflammation and chemical 
sensitisation they then become responsive and discharge vigorously even 
during ordinary movement. They also display changes in receptive fields. The 
properties of these receptors still require characterisation, but they have been 
identified in a number of different tissues and species and are termed "silent" 
nociceptors. 
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PRE-EMPTIVE ANALGESIA 
 
Preemptive analgesia20,21,22 is an attractive concept of addressing pain 
even before it starts. The concept was propounded in the early 1980s when 
experimental studies showed that measures to antagonize the nociceptive 
signals before injury prevented central hypersensitisation, thereby reducing 
the intensity of pain following the injury. Transmission of pain signals evoked 
by tissue damage leads to sensitization of the peripheral and central pain 
pathways. Pre-emptive analgesia is a treatment that is initiated before the 
surgical procedure in order to reduce this sensitization. Owing to this 
‘protective’ effect on the nociceptive system, pre-emptive analgesia has the 
potential to be more effective than a similar analgesic treatment initiated after 
surgery. Theoretically, immediate postoperative pain may be reduced and the 
development of chronic pain may be prevented. Although some clinical 
studies have demonstrated significant effects on acute postoperative pain, no 
major clinical benefits of pre-emptive analgesia have been documented. The 
only way to prevent sensitization of the nociceptive system might be to block 
completely any pain signal originating from the surgical wound from the time 
of incision until final wound healing. It refers to the administration of an 
analgesic before a painful stimulus, such as tissue injury during surgery, in an 
attempt to obtain better pain relief compared with when the same analgesic 
intervention is used after the painful stimulus. Preemptive analgesia is known 
to prevent central sensitization of pain, thereby reducing hyperalgesia. There 
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is also the “wind-up” phenomenon which causes persistent spontaneous pain 
even in the absence of peripheral stimuli. 
 Preemptive analgesia is defined as an anti-nociceptive treatment that 
prevents the establishment of altered central processing of afferent input, 
which amplifies postoperative pain. By decreasing the altered central sensory 
processing, preemptive analgesia is thought to consequently decrease the 
incidence of hyperalgesia and allodynia after surgery. The definition of 
preemptive analgesia has varied, thereby causing confusion and 
misunderstanding of the concept. It is important to consider this definition in 
clinical trials for determining the effectiveness of preemptive analgesia. The 
emphasis of preemptive analgesia is on the pathophysiologic phenomenon 
that it should prevent altered sensory processing. Therefore, preemptive may 
not simply mean “before incision.” An insufficient afferent blockade cannot be 
preemptive, even if it is administered before the incision. 
Hence, the primary goals of preemptive analgesia are  
1. To decrease acute pain following tissue injury 
2. To prevent pathological modulation of the central nervous system 
(CNS) due to this pain and 
3. To prevent development of chronic pain. 
In the present study, i.v paracetamol was used as a preemptive 
analgesic in relieving post operative pain. 
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PHARMACOLOGY OF PARACETAMOL 
History: 
In 1877, Harmon Northrop Morse synthesized Para-acetyl-amino-
phenol at John Hopkins University. But it wasn’t until 1887 that Joseph Von 
Merring tried Paracetamol on patients. Paracetamol was first used in medicine 
by Von Mering in 1893. It gained popularity only after 1949. Paracetamol was 
marketed in USA in 1953 and introduced as a 500mg tablet in the UK in 1956. 
Structure of Paracetamol  
Para-acetyl-amino-phenol 
 
Composition of IV Paracetamol 
1) Cysteine Hydro Chloride Mono hydrate. 
2) Di Sodium Phosphate di hydrate. 
3) Hydro chloric acid. 
4) Mannitol. 
5) Sodium hydroxide. 
6) Water for injection. 
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Mechanism of action8 
 
The mechanism of action remains unclear as , unlike opioids and 
NSAIDs, paracetamol has no known endogenous binding sites and does not 
inhibit peripheral cyclooxygenase activity significantly. There is increasing 
evidence of a central antinociceptive effect, and potential mechanisms for this 
include inhibition of a central nervous system COX-2, inhibition of a putative 
central cyclooxygenase ‘COX-3’ that is selectively susceptible to paracetamol, 
and modulation of inhibitory descending serotinergic pathways. Paracetamol 
has also been shown to prevent prostaglandin production at the cellular 
transcriptional level, independent of cyclooxygenase activity. Paracetamol is 
therefore an effective postoperative analgesic, with potency slightly less than 
a standard dose of morphine or the NSAIDs. The introduction of an i.v. 
preparation and reports of the analgesic and anti-inflammatory properties and 
safety advantages of a nitric oxide (NO) releasing form may represent 
significant advances in the use of this drug. Paracetamol acts on both the 
peripheral and central component of pain pathway. Paracetamol inhibits both 
isoforms of cyclo-oxygenase (COX); the constitutive COX 1, and the inducible 
COX-2. Non-steroidal anti-inflammatory drugs (NSAIDs) also act by inhibition 
of COX, yet important differences exist; notably, paracetamol displays weak 
anti-inflammatory activity, few or no gastrointestinal, and only a small dose-
dependent alteration of platelet function. Recent studies show that it is a cox-3 
inhibitor23,24 which is a splice variant of cox-1 which selectively inhibits the 
nervous system prostaglandin synthesis. Other central mechanisms of action 
depend on the bulbo-spinal serotoninergic pathway25,26. It is also an indirect 
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activator of cannabinoid CB1 receptors. By direct inhibition of the NMDA 
receptor it inhibits the substance P dependent synthesis of nitric oxide which 
is a primary mediator of nociception. Paracetamol has analgesic and 
antipyretic effects similar to those of aspirin. It has only weak anti 
inflammatory affects. It has a poor ability to inhibit cyclooxygenase (COX) in 
the presence of high concentration of peroxides as are found at the sites of 
inflammation. COX might be disproportionately pronounced in the brain 
explaining the antipyretic activity of paracetamol.  
 
Pharmacodynamics27: 
 
Intravenous Paracetamol is very well tolerated.  Hypersensitivity 
reactions are rare. Onset of analgesia occurs rapidly within 5-10 mins of IV 
administration. Peak analgesic effect occurs in 1 hour with a mean duration of 
4-6 hours. The antipyretic effect of IV pracetamol is also rapid with fever 
reduction within 30 minutes of administration and lasting for at least 6 hours. 
Single or repeated therapeutic doses have no effect on the cardio-vascular 
and respiratory systems, on platelets or on coagulation. Acid base changes, 
uricosuric effects do not occur. The drug does not produce gastric irritation, 
erosion, or bleeding as with salicylates. 
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Pharmacokinetics 27,28 
 
Paracetamol displays linear pharmacokinetics at dosages of 4-8/ gm per 
day. Following single dose of paracetamol 1gm, the mean maximum plasma 
concentration (Cmax) was  29.9 µg/ml at the end of 15-min infusion period. 
Cmax was approximately two fold higher after IV paracetamol than after oral 
paracetamol. Mean volume of distribution for IV Paracetamol 1g was 85 L. It 
rapidly penetrates into CSF and does not extensively bind to plasma proteins. 
It is not subjected to significant first pass metabolism. Oral bioavailability is 
estimated between 63 – 89%. Therapeutic level for action is only a plasma 
concentration of 10 – 20 µ/ml whereas the threshold for potential 
hepatotoxicity is 150 µ/ml. Hence there is a wide margin of safety between 
therapeutic dose and toxicity. 
 
Metabolism 29,30,31 
 
Metabolized in the liver by glucuronidation and sulfation. At higher 
doses it is metabolized by the cytochrome p450 enzyme pathway to produce 
the reactive intermediate N-acetyl-p-benzo-quinone imine (NAPQI). Toxic 
effects are due to this metabolite. NAPQI is eliminated by the liver by a 
reaction with tripeptide glutathione. If not eliminated, NAPQI begins to react 
with cellular proteins & nucleic acids causing irreparable damage. 
  
At therapeutic doses, only a small fraction (<4%) is metaboli
cytochrome P450 to a reactive intermediate N
(NAPQI) which is responsible for toxicity in many organs, including the liver.
Although the major concern with paracetamol administration relates to the 
potential for hepatotoxicity, this is extremely rare following therapeutic 
dosing31. In patients with severe disease
half-life can be prolonged. 
catalysing NAPQI formation, but inhibits its activity while it remains in the 
body. Under normal conditions, NAPQI is rapidly detoxified by reduced 
glutathione and eliminated in the urine. 
with paracetamol may initially be protective, but once alcohol is cleared from 
the body, the risk of hepatotoxicity from overdose is increased
adults, hepatotoxicity may occur after a single dose of 10 to 15g (150 to 
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-acetyl-p-benzoquinone imine 
32,33,34,35, however, the elimination 
Alcohol induces CYP2E1, the main enzyme 
Therefore co-administration of alcohol 
 36,37
zed by 
 
,38. In 
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250mg/kg) of paracetamol because the glutathione stores are exhausted by 
the generation of large amounts of NAPQI.Therapeutic dosing may elevate 
serum alanine aminotransferase (ALT) in healthy adults who consume alcohol 
in moderation or not at all, but isolated elevations in aminotransferases are 
unlikely to be of clinical significance.39,40,41 Paracetamol has recently been 
shown to have a dose dependent anti-aggregatory effect on platelets, 
mediated through inhibition of platelet COX-1 and subsequent decreased 
synthesis of thromboxane A2
42. Inhibition is observed after a standard dose of 
15 mg.kg, but the degree of inhibition is significantly less than is seen with 
NSAIDs such as diclofenac 43, and surgical bleeding attributable to 
paracetamol is unlikely. 
 
Elimination 
 
Metabolites are excreted in the urine as glucuronide (60-80%) and 
sulfide (20-30%) conjugates with less than 5% of the drug excreted 
unchanged. Less than 1% is recovered in bile. Elimination half life of 
Paracetamol 1g is 2.7 hours and its rate of systemic clearance is 17.9 litres 
per hour.  
 
In Paediatrics 44,45: 
1) Neonates and children upto 10 yrs of age excrete less glucuronide 
conjugates and more sulfate conjugates than adults. 
2) Elimination half life is shorter in children (1.5 – 2 hrs than adults) and 
longer in neonates (3.5 hrs) 
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3) Pharmacokinetics is similar to that of adults with the exception of t1/2 ß 
4) t1/2ß is shorter in children (1.5-2.0 hrs) than adults, lower in neonates,(3.5 
hours) than adults. Systemic clearance rate of IV Paracetamol (10, 12.5 
or 15 mg/kg) for neonates aged 28-32 weeks, 32-36 week and >36 week 
was estimated to be 5.24 L/h/70 kg, with a Volume of distribution of 
76L/70 kg. Clearance rate increases with gestational age. 
 
Elderly 
Pharmacokinetics is not changed in elderly subjects. 
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MATERIALS AND METHODS 
Study design: 
Prospective, randomized, double blinded, comparative study. 
Double blinding was done by taking appropriate dose of 
intravenous paracetamol calculated in mg/kg and was added to a solution of 
normal saline to make a volume of 100 ml. This was labelled as drug A. Plain 
100 ml of normal saline was labelled as drug B. Neither the person 
administering the drug nor the person observing the patient in the post 
operative period did not know the drug. 
 
Study population: 
After obtaining the institutional ethical committee approval and written 
informed consent from the parent/guardian, 70 ASA I physical status patients 
undergoing tonsillectomy were selected between the age group of 6-16 years 
and weighing between 10-30 kg.  
 
Sample size: 
35 patients in the paracetamol group (P group) and 35 in the control 
group (N group).  
Probability sampling: All the70 patients were randomised in two groups 
and the entire patients stood an equal chance of getting into any group. 
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Data collection:  
• Age, Sex, Weight 
• Pre operative and intra operative pulse rate and blood pressure, Spo2 
• Duration of  surgery 
• Sedation score using Ramsays Sedation Scale 
• Visual analogue pain scale at the end of surgery, 1h 2h,3h,4h,5h,6h. 
• Post operative complications such as 
 Drug intolerance 
 Nausea and vomiting 
 Epigastric pain 
 Bleeding 
Exclusion criteria 
• Upper and lower respiratory tract infections 
• Cardiac valvular abnormalities 
• Abnormal bleeding and clotting time 
• Obstructive sleep apnea 
• Known history of allergy to paracetamol  
• Past history of jaundice  
• Patients on aspirin 
• Any other concurrent antipyretic, analgesic or anti inflammatory 
medications 
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PRE OPERATIVE EVALUATION:- 
History regarding previous anaesthesia, surgery, any significant 
medical illness, medications and allergy were recorded. Age, Inpatient 
Number, Body Weight, Baseline vital parameters were recorded. Complete 
physical examination and airway assessment were done.  
 
Following laboratory investigations were done: 
• Blood grouping and typing 
• Complete Hemogram  
• Coagulation profile 
• Blood: sugar, urea 
• Serum Creatinine 
• Serum Electrolytes: Na+, K+ 
• ECG in all leads 
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Ethical committee approval 
Informed consent 
Randomization 
Group P (35) Group N (35) 
Premedication 
Injection glycopyrolate 0.004mg/kg i.m 
Injection midazolam 0.07mg/kg i.m. 
 
Iv cannulation with 20G iv cannula 
IV paracetamol given 15 minutes before the start of the procedure 
Group P 
Iv Paracetamol 15mg/kg infusion 
of 100ml over 15 minutes 
 
Group N 
normal saline 100ml infusion as   
placebo. 
Monitors 
ECG 
SPO2 
NIBP 
Pre Oxygenation for 5 minutes 
Inj Fentanyl 2 mcg/kg 
Inj.thiopentone 5mg/kg 
Inj.rocuronium 0.6 mg/kg 
 
I.V 
Intubation with appropriate size cuffed endotracheal  
tube nasally.Position of endotracheal tube confirmed  
 
ANAESTHESIA PROTOCOL: 
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Controlled ventilation using circle absorber with 
N2O 66% + O2  33% + Halothane 0.5-1% 
Reversal with neostigmine 0.04mg/kg and glycopyrolate 0.008mg/kg 
Extubation after adequate regain of reflexes 
Evaluate VAPS 
Shift to PACU 
High Flow Oxygen Therapy and Monitors 
Evaluate VAPS at hourly intervals 
 Terminate at 6 hours  
Shift to routine pain protocol 
   
                                                  
 
 
 
 
 
 
  
 
 
 
 
 
Post-operatively the patients were monitored for changes in pulse rate, 
MAP, Spo2 for a period of 6 hours and were instructed to mark a point on the 
10 point visual analog pain scale according to the intensity of pain.  The pain 
relief was graded as follows in VAPS. 
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VISUAL ANALOG PAIN SCALE 
 
Pain Score Quality of analgesia 
0 -1 Excellent 
2 – 4 Good 
5 – 6 Fair 
7 – 8 Poor 
9 – 10 No relief 
 
 The pain score was assessed for a period of 6 hours and the total 
duration of post operative analgesia was taken as the period from the end of 
surgery till the first requirement of systemic analgesic medication. 
 
In both the groups patients were given the first analgesic medication 
when the VAPS score was 4 and above.  Patients were observed for any side 
effects like intolerance, bleeding, epigastric pain, PONV. 
 
Sedation score was assessed using Ramsays sedation scale52 as 
follows. 
1. Anxious and agitated or restless, or both  
2. Co-operative, oriented, and calm  
3. Responsive to commands only  
4. Exhibiting brisk response to light glabellar tap or loud auditory stimulus  
5. Exhibiting a sluggish response to light glabellar tap or loud auditory 
stimulus  
6. Unresponsive  
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OBSERVATION AND RESULTS 
 
Data were analysed using SPSS version 13.0 computer software at 
level of significance p = 0.05. Numerical variables were presented as mean 
and standard deviation (SD) and categorical variables were presented as 
frequency (%). Unpaired Student ‘t’ test was used for between-group 
comparisons between categorical variables. Time to first analgesic 
administration was analysed by the Kaplan–Meier survival analysis. 
 
 COMPARISON 
AGE GROUP 
YRS 
PARACETAMOL
No
5 – 9 16
10 – 14 18
15 – 19 1 
TOTAL 35
MEAN ±SD 
Significance 
 
 
 The mean ages between the two groups were 9.7 ± 1.9 and 9.8 ± 2.8 
for P and N group respectively. The difference between two mean ages was 
not statistically significant (P>0.05).
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OF THE TWO GROUPS BY THEIR AGE 
Group P 
 
Group N 
PLACEBO 
Total
 % No % No 
 45.7 17 48.6 33 
 51.4 16 45.7 34 
2.9 2 5.7 3 
 100 35 100 70 
9.7 ± 1.9 9.8 ± 2.8 9.8 ± 2.7
P = 0.898 Not significant 
 
10 – 14 15 – 19
18
1
16
2
Age Group in Years
 
% 
47.1 
48.6 
4.3 
100 
 
 
 
Group P
Group N 
 SEX 
Group P 
No %
Male  17 48.6
Female  18 51.4
Total  35 100
 
 
 
 The ratio of male to female remained 
The difference in percentage between two groups was not statistically 
significant.  
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SEX DISTRIBUTION 
Group N 
‘t’ value Significance
 No % 
 18 51.4  
0.273 P>0.05 17 48.6 
 35 100 
the same in both P and N groups. 
 
Group N
51.4
48.6
Sex Distribution
Female 
Male 
 
 
 
 
 Matching of the P and N group with reference to their body weight
WEIGHT 
Kgs 
10 – 15 
15 – 20 
20 – 25 
25 – 30 
30 – 35 
35 – 40 
TOTAL 
MEAN ± SD
‘t’ 
Significance
 
 
 The mean weights between the two groups 
3.5 for P and N group respectively. The difference between two
was not statistically significant (P > 0.05).
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Group P 
PARACETAMOL 
Group N 
 
No % No % 
8 22.9 9 25.7 
4 11.4 4 11.4 
9 25.7 8 22.9 
11 31.4 8 22.9 
2 5.7 6 17.1 
1 2.0 0 0 
35 100 35 100 
 20.4 ± 6.3 20.3 ± 6.7 
0.036 
 P = 0.971 NS 
were 61.1 ± 3.2 and 59.7 ± 
 mean weights 
 
 
– 20 20 – 25 25 – 30 30 – 35 35 – 40
4
9
11
2
1
4
8 8
6
0
Weight in Kgs
Group P
Group N
 
 
  
Measured 
variables 
 
Group P 
Mean  S.D 
Duration of 
surgery 
(min) 
43.9 5.7
 
The duration of surgery 
found statistically not significant.
 The two groups were compared with reference to their age,
and duration of surgery and they were amenable for comparison of other 
variables like duration of analgesia and haemodynamic 
MAP, PR and SpO2. 
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Duration of surgery 
 
Group N 
   
   ‘t’ 
 
 
Significance
 mean S.D 
 43.7 5.7 0.105 P > 0.05 NS
for both groups was comparable and was 
 
 sex,
variables such as 
Group N
43.9
43.7
 
 
 
 weight 
 Comparison of duration of analgesia
Variable 
P group 
Mean SD Mean
Duration of 
analgesia 
(hrs) 
6.1 0.5 
 
 
 
 Stastistically significant
in the paracetamol group lasting for about 
period as compared to placebo group which was only 2.6 hours.
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N group Mean 
Difference 
‘t’ Diff significance
 SD 
2.6 0.3 3.5 33.608 68 P < 0.001
 (p<0.001) prolongation of duration of analgesia 
6.1 hours in the postoperative
 
N group
6.1
2.6
 
 
 
 
 Comparison of hemodynamic variables between the two 
Hemodynamic variables in the pre operative period
 
Measured 
variables 
 
Group P
Mean 
Pulse rate 94.8 
MAP 65.6 
SpO2 99.5 
 
The pulse rate, MAP and SpO
no statistically significant difference between
(p>0.05) 
0
20
40
60
80
100
Group P
51 
groups 
 
 
 
Group N 
 
‘t’ 
 
 
Significance
S.D mean S.D 
6.1 95.3 6.0 0.376 P = 0.376 
NS 
0.6 65.4 0.8 1.030 P =0.307 NS
0.5 99.7 0.5 1.695 P = 0.095 
NS 
2 of both groups reveals that there was 
 both the groups before surger
Group N
PR
MAP
SpO2
 
 
 
y 
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Hemodynamic variables in the intra operative period 
Time 
interval 
 
variables 
Group P Group N 
 
‘t’ 
 
Significance Mean SD mean SD 
Just 
after 
induction 
PR 102.7 4.5 103.7 5.2 0.886 P = 0.379 
MAP 69.4 0.6 69.6 0.8 1.030 P = 0.307 
SpO2 99.5 0.5 99.5 0.5 0 P = 1 
 
5 min 
PR 100.5 4.3 103.7 5.2 0.886 P = 0.379 
MAP 67.7 0.7 67.8 1.1 0.663 P = 0.510  
SpO2 99.7 0.5 99.7 0.5 0 P = 1 
 
15min 
PR 99.3 4.3 100.5 5.0 1.076 P = 0.286 
MAP 66.7 0.8 66.9 0.9 1.247 P = 1.247 
SpO2 99.5 0.5 99.5 0.5 0 P = 1 
 
30 min 
PR 98.2 4.2 99.5 5.1 1.154 P =  0.254 
MAP 66.1 1.2 66.6 1.2 1.902 P = 0.061 
SpO2 99.5 0.5 99.5 0.5 0 P = 1 
 
End of 
surgery 
PR 100.0 4.0 100.8 4.7 0.709 P = 0.481 
MAP  66.7 1.6 69.5 0.7 9.5 P = 0.061 
SpO2 99.5 0.5 99.5 0.5 0  P = 1  
 
 
 
 
 
 
 Hemodynamic variables in the intra operative period
 
 
The pulse rate, MAP and SpO
no statistically significant 
(p>0.05) 
 
 
 
 
 
 
53 
 
2 of both groups reveals that there was 
difference between both the groups during 
 
 
surgery 
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Post operative haemodynamic variables        
                                                                                                                                                          
Time 
interval 
variables 
Group P Group N 
‘ t ‘ Significance 
Mean SD Mean SD 
 
1 hr 
PR 94.6 3.3 100.1 4.7 5.701 P = 0.000 
MAP 63.5 0.9 66.9 1.3 12.540 P = 0.000 
SpO2 99.7 0.5 99.5 0.5 1.450 P = 0.152 
 
2 hr 
PR 94.9 2.7 100.2 4.5 5.905 P = 0 
MAP 64.4 1.2 67.8 1.2 11.724 P = 0 
SpO2 99.7 0.5 99.5 0.5 1.450 P = 0.152 
 
3 hr 
PR 95.8 2.7 101.9 4.4 6.945 P = 0 
MAP 64.7 1.1 67.8 1.2 11.159 P = 0 
SpO2 99.5 0.5 99.7 0.5 1.209 0.231 
 
4 hr 
PR 96.1 2.9 103.1 4.6 7.672 P = 0 
MAP 65.2 1.1 68.8 1.2 13.454 P = 0 
SpO2 99.5 0.5 99.5 0.5 0.236 P = 0.814 
 
5 hr 
PR 97.5 2.5 104.3 4.4 7.942 P = 0 
MAP 65.9 1.3 69.6 1.3 12.163 P = 0 
SpO2 99.5 0.5 99.5 0.5 0 P = 1  
 
6 hr 
PR 99.4 2.6 105.7 4.1 7.572 P = 0 
MAP 66.8 1.1 70.3 1.1 12.781 P = 0 
SpO2 99.7 0.5 99.5 0.5 1.450 P = 0.152 
 
 
 Post operative haemodynamic variables       
As shown in the table above, the mean pulse rate at 0 
post operative period for P group was significantly lower than the N group with 
P < 0.001.  The mean MAP at 0 
significantly higher in N group than P group with P < 0.001. There was no 
significant difference in respect to mean post operative SpO2 in both groups.
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– 6 hours in the 
– 6 hrs in the post operative period was 
 
 
 
 Post operative 
Time 
interval 
   Group P
Mean  
EOS 2.9 
1 hr 2.6 
2 hr 2.0 
3 hr 1.7 
4 hr 1.0 
5 hr 1.0 
6 hr 1.0 
 
Statistically significant 
paracetamol group with a score of 2.6
second hour, 1.7 at the end of 3 hours after that both the grou
mean score of 1 up to six hours in post operative period. 
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Sedation score 
 Group N 
‘ t ‘ Significance
SD Mean  SD 
0.3 1.9 0.2 15.576 P < 0.001
0.5 1.0 0 19.653 P < 0.001
0.0 1.0 0.0 0 0 
0.4 1.0 0.0 9.911 P < 0.001
0.0 1.0 0.0 0 0 
0.0 1.0 0.0 0 0 
0.0 1.0 0.0 0 0 
conscious sedation was observed in
 at the end of first hour, 2 at the end of 
ps were with a 
 
 
 
 
 
 
 
 Post operative pain assessment using visual analog pain scale
 
57 
 
 
 
 This graph compares the quality 
score between 0-10 with 0 being excellent pain relief and score of 10 being 
the worst pain ever. Patients in
in the form of intramuscular 
than 4. In the P group all 
duration of 6 hours while in the N group a VAPS
before the end of 2.5 hours and rescue analgesic was given.
 
 
Kaplan Meier survival curve
The Kaplan Meier survival curve shows
the patients in respect to time to 
shows the existence of post operative 
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of analgesia assessed by using
 both the groups were given rescue analgesic 
diclofenac 1.5mg/kg if the VAPS score was
patients had a VAPS score of 4 after 
 score of 4 was attained even 
 
 
 the cumulative survival of all 
analgesic requirement .The above graph
analgesia in both the groups 
 VAPS 
 more 
a mean 
 
 
.In the P 
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group 62.9%of the patients had been continuing analgesia upto 6 hours and 
the remaining 37.1% had been experiencing analgesia upto a period of 8 
hours in the post operative period. But the same analgesic effect was present 
in the N group only upto 4 hours after which there were no patients continuing 
the analgesia. 
 
 
 
Adverse effects 
 Group P Group N  
Intolerance  0 0 
Bleeding  0 0 
Epigastric pain 0 0 
PONV 0 0 
 
There were no adverse events observed in both the groups. 
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DISCUSSION 
 
Tonsillectomy 46 is one of the most frequently performed surgical 
procedures, and its main indication is severe recurrent tonsillitis. The tonsils 
and adenoids are part of Waldeyer's ring of lymphoid tissue around the 
pharynx and are often the sites of acute and chronic inflammation. 
Tonsillectomy and adenoidectomy are not minor procedures; they involve a 
shared airway, often in a small child, with difficult access, obstructive airway 
symptoms, and the potential for blood contamination of the lower airway. 
Mortality associated with tonsillectomy ranges from 1:40,000 to 1:12,000. The 
provision of adequate analgesia after tonsillectomy presents the 
anaesthesiologist with difficulties as this is a painful procedure and may be 
associated with significant bleeding into the airway2 
Recommended approaches for post operative pain management is to 
initiate therapy with analgesics such as paracetamol, NSAIDS, aspirin and 
opioids. Opioids when used to provide effective postoperative analgesia for 
tonsillectomy may be associated with side effects like sedation, respiratory 
depression and vomiting47,48 which may make recovery hazardous after 
pharyngeal surgery particularly in children. Non-steroidal anti-inflammatory 
drugs not only produce good analgesia but also avoid the side effects of 
opioids. Peri-operative use of NSAIDS has been limited because of concerns 
over increased postoperative bleeding, which has been demonstrated with 
ketorolac49,50 although apparently not for other NSAIDS51. Paracetamol is an 
effective analgesic and an antipyretic agent 3,4. Efficiency and tolerability for 
Paracetamol are well established35. It has a favourable safety profile and it is 
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the most commonly prescribed drug for the treatment of mild to moderate 
pain. Recent studies have exposed the role of intravenous (IV) Paracetamol in 
post-operative pain relief5,6,7,8,9,10,11,12,13,14,15. 
 
Atef A, Fawaz AA.et al5 reported that iv paracetamol administered 
regularly in adult patients with moderate to severe pain after tonsillectomy, 
provided rapid and effective analgesia and was well tolerated as compared to 
placebo. The present study also compared the analgesic efficacy and 
tolerability of IV Paracetamol where in, the administration of 15mg/kg of 
paracetamol IV provided analgesia upto 6 hours in the post operative period 
which was superior to placebo in managing postoperative pain. 
 
Alhashemi JA et al6  compared i.v. acetaminophen 15mg/kg with 
intramuscular (i.m.) meperidine 1mg/kg in eighty children undergoing 
tonsillectomy and observed that objective pain score (OPS scores) were 3.1  
for the acetaminophen group and 2.1  for the meperidine group (P=0.147); 
however, Ramsay sedation scores were 3 and 4 for the acetaminophen and 
meperidine groups, respectively(P<0.05). In the present study also ramsays 
sedation score was used to compare level of sedation. In the paracetamol 
group sedation score was 2.9 at the end of surgery,score of 2.6 at the end of 
first hour,2 at the end of second hour,1.7at the end of 3 hours and after that 
both the groups were with a mean score of one up to six hours in post 
operative period. Thus i.v paracetamol produced acceptable sedation in the 
post operative period without any compromise to the airway. 
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In another study T.Alhashemi JA,et al7 reported that intraoperative iv 
paracetamol in comparison with i.m meperidine resulted in higher pain scores 
but earlier readiness for recovery room discharge in paediatric patients 
undergoing dental restoration. In the present study, i.v paracetamol had better 
recovery profile as compared to placebo and better pain relief with no adverse 
effects. 
 
Mehmet Turan Inal et al15 compared the quality of analgesia and side 
effects of iv paracetamol versus meperidine for postoperative analgesia in 
parturients undergoing elective caesarean section  in a randomised double-
blind study. In the meperidine group the VAS scores after the operation were 
higher than paracetamol group. But in the paracetamol group most of the 
patients had lower VAPS and had the first rescue analgesic six hours after the 
operation. They concluded that i.v. paracetamol has better analgesic potency 
than i.v. meperidine for postoperative analgesia after caesarean section. In 
the present study also there was lower VAPS score in the paracetamol group 
with the time to first rescue analgesic after a mean duration of 6 hours.  
 
Ahmed AI Fadly et al11 studied the analgesic effect of intravenous 
paracetamol, morphine and their combination for post operative pain after 
release of post burn neck contractures. They concluded that IV paracetamol 
effectively reduces morphine requirements by 60% or even replace it, with 
reduced incidence of adverse events and a safer course during postoperative 
pain management after release of post burn neck contracture in adults. In the 
present study also there were no adverse events and the time to first rescue 
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analgesia was significantly longer in the paracetamol group as compared to 
the placebo group with mean duration of pain relief upto a period of 6 hours. 
 
Cattabriga et al13 conducted a placebo-controlled, double-blinded, 
randomized trial to study the efficacy of intravenous paracetamol as an 
adjunctive analgesic to a tramadol-based background analgesia after cardiac 
surgery. Postoperative pain was evaluated by visual analog scale. A rescue 
dose of 2—5 mg of intravenous morphine was administered whenever the 
VAPS score was greater than 3. Patients who received paracetamol had 
significantly less pain at rest (p = 0.0041, 0.0039, 0.0044, respectively); after 
this time the two groups did not differ. Paracetamol group required less 
cumulative morphine than placebo group .They concluded that iv paracetamol 
in combination with tramadol provides effective pain control. But in the present 
study, the postoperative pain was evaluated by visual analog scale and a 
rescue dose of 1.5 mg/kg of i.m diclofenac was administered whenever the 
VAPS score was greater than 4. Here Iv paracetamol provided effective pain 
control in the post operative period upto a period of 6 hours. 
In the present study, the mean pulse rate at 0 – 6 hours in the post 
operative period for P group was significantly lower than the N group (P < 
0.001).  The mean MAP at 0 – 6 hrs in the post operative period was 
significantly higher in N group than P group (P < 0.001). These statistics 
explain the analgesic efficacy of paracetamol which resulted in a stable 
hemodynamic status.  Thus IV Paracetamol produced a better haemodynamic 
profile in the post-operative period.  
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Statistically significant conscious sedation was observed in 
paracetamol group with a score of 2.6 at the end of first hour, 2 at the end of 
second hour, 1.7 at the end of 3 hours after that both the groups were with a 
mean score of one up to six hours in post operative period. This explains the 
analgesic efficacy of paracetamol which rendered the children calm, co-
operative and tranquil in the post-operative period. Moreover, paracetamol 
was well tolerated by the pediatric population and no adverse effects were 
noted during the study. 
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SUMMARY 
 
1. Intravenous Paracetamol achieved significant post operative pain 
relief up to 6 hours. 
2. Intravenous Paracetamol delayed the requirement of first dose of 
rescue analgesic for a mean duration of 6 hours in the post-operative 
period. 
3. Intravenous Paracetamol had a better haemodynamic profile in the 
post-operative period. 
4. Intraveous Paracetamol had a smooth and better post-operative 
recovery profile rendering a calm, co-operative and tranquil patient. 
5. Intravenous Paracetamol did not exhibit any adverse effects in the 
patients. 
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CONCLUSION 
 
1. Intravenous Paracetamol can be used as an effective analgesic for 
providing pre-emptive analgesia. 
2. Intravenous Paracetamol provides excellent post operative pain 
relief.  
3. Intraveous Paracetamol has a better hemodynamic profile. 
4. Intraveous Paracetamol is safe for use in  patients 
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PROFORMA 
Name:                                       Age:               Sex:              Wt:     kg 
Date :                                        I.P. no:           ASA: 
History : 
 
Investigations : 
                             Hb%:                                                                    urine 
albumin:     
                 Blood sugar:                                                                                 
sugar: 
                           Urea:                                                                               
deposits: 
                   Creatinine:                                              BT:                                   
CT: 
O/E 
               Anaemia:                                        CVS;                           RS:  
                         PR:                                                                            BP: 
Pre-med     : Inj. Midazolam  0.07mg/kg i.m   
          Inj. Glycopyrrolate 0.004mg/kg i.m.  45 min prior to surgery 
Group P   :  I.V. paracetamol 15mg/kg infusion  15 minutes                                                            
before the start of the procedure 
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Group N   :   Normal saline infusion 100ml   15 minutes                                                             
before the start of the procedure 
Induction  :    Inj Fentanyl 2 mcg/kg 
                    Inj.thiopentone 5mg/kg 
                    Inj.rocuronium 0.6 mg/kg 
Airway       :    ETT 
Maintenance : O2 / N2O / Halothane  
Parameters Monitored: 
Intra op; 
Time in min   Haemodynamic variables 
 PR MAP SpO2 
Just after 
induction (JAI) 
   
5 min    
15 min    
30min    
End of surgery 
(EOS) 
   
 
Duration of surgery : 
Post operative : 
Time in hrs Haemodynamic variables Sedation 
score 
VAPS 
PR MAP SpO2   
1 hr      
2 hr      
3 hr      
4 hr      
5 hr      
6 hr      
 
Time to first analgesic requirement : 
Side effects : Epigastric pain / Bleeding / Intolerance / PONV 
SNO NAME AGE/SEX WEIGHT PREOP DOS
P SPO2 BP JAI 5 MIN 15 MIN 30 MIN EOS JAI 5 MIN 15MIN 30MIN EOS
1 SATHIK 8/M 18kg 100 100 65 45MIN 108 104 104 102 105 100 100 99 100 100
2 MAHESKUMAR 11/M 25KG 94 99 66 45MIN 100 96 97 96 98 99 100 99 99 99
3 FEROZBANU 14/F 25KG 90 99 66 45MIN 98 97 96 95 98 99 100 99 99 99
4 MADHU 6/M 10KG 104 100 66 40MIN 110 108 106 104 100 100 100 99 100 100
5 INDHUMATHI 12/F 25KG 90 99 66 60MIN 100 98 97 96 96 99 100 99 99 99
6 SARASWATHI 10/F 20KG 92 100 66 45MIN 100 98 97 96 97 100 100 99 100 100
7 VIGNSEH 7/M 20KG 100 99 65 50MIN 110 106 106 105 106 99 100 99 99 99
8 ROHINI 13/F 25KG 90 100 66 35MIN 100 98 97 96 100 100 100 99 100 100
9 SABEENA 12/F 30KG 86 99 66 40MIN 96 95 93 92 96 99 100 99 99 99
10 MUTHULAKSMI 8/F 12KG 100 100 65 45MIN 108 106 103 103 105 100 100 99 100 100
11 KARTHIK 12/M 25KG 92 99 66 45MIN 100 98 97 96 96 99 100 99 99 99
12 VIGNESH 16/M 35KG 82 99 65 45MIN 96 94 92 90 94 99 100 99 99 99
13 ABISHA 7/F 20KG 98 99 66 45MIN 106 104 102 100 102 99 100 99 99 99
14 HARI 6/M 15KG 98 99 66 40MIN 107 105 102 100 102 99 100 99 99 99
15 SELVARAJAN 8/M 20KG 98 100 66 40MIN 106 104 102 100 102 100 100 99 100 100
16 SIVANASH 7/M 14KG 100 100 66 35MIN 108 106 104 102 105 100 100 99 100 100
17 SABERNISHA 7/M 20KG 99 100 66 40MIN 107 104 103 102 105 100 100 100 100 100
18 JAMIMA 9/F 15KG 96 100 66 45MIN 104 101 101 100 104 100 100 100 100 100
19 NATCHIAYAR 10/F 25KG 94 99 66 45MIN 99 96 96 98 102 99 99 100 99 99
20 HEMALKUMAR 6/M 12KG 106 99 65 50MIN 108 105 103 103 105 99 100 100 99 99
21 GRACE 6/F 10KG 104 99 65 40MIN 105 103 102 101 105 99 100 100 99 99
22 MUTHULAKSMITHA 12/F 25KG 90 100 65 60MIN 100 98 97 96 96 100 100 100 100 100
23 PRAVEEN 10/M 20KG 92 100 65 45MIN 100 98 97 96 97 100 99 100 100 100
24 PRIYA 7/F 14KG 100 100 65 50MIN 107 106 106 105 106 100 99 100 100 100
25 KRISHNA 13/M 25KG 90 100 65 35MIN 100 98 97 96 100 100 99 100 100 100
26 ANDAL 12/F 26KG 86 100 66 40MIN 96 95 93 92 96 100 99 100 100 100
27 SARADHA 8/F 12KG 100 99 66 45MIN 108 107 106 105 105 99 99 100 99 99
28 VISHAL 12/M 22KG 92 99 66 45MIN 100 98 97 96 96 99 99 100 99 99
29 KUMAR 14/M 26KG 82 99 66 45MIN 96 94 92 90 94 99 99 100 99 99
30 ANITHA 7/F 15KG 98 99 66 45MIN 106 104 102 100 102 99 99 100 99 99
31 YASIM 7/F 12KG 100 100 64 35 MIN 106 104 102 100 102 100 99 100 100 100
32 SARNYA 10/F 20KG 96 100 66 45MIN 100 98 97 96 97 100 99 100 100 100
33 YALATHI 10/F 20KG 98 99 65 40MIN 102 100 100 99 95 99 99 100 99 99
34 ESSAKI 11/M 25KG 94 99 65 45MIN 100 98 97 96 96 100 100 100 100 100
35 KALIRAJ 12/M 30KG 87 99 66 40MIN 96 95 93 92 96 99 100 99 99 99
PR SPO2
Group P
INTRAOP 
INTRAOP
JAI 5 MIN 15 MIN 30 MIN EOS 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
69 68 67 66 67 97 97 98 99 99 103 100 100 99 100 100 100 65 63 65 66 66 68
70 66 65 65 66 95 95 96 96 98 99 100 100 99 99 99 100 65 63 63 66 68 70
70 66 66 65 67 93 93 94 94 95 96 100 100 99 99 99 100 63 64 64 65 67 68
69 68 68 66 67 96 95 96 97 98 100 100 100 99 100 100 100 64 66 66 67 68 68
70 68 67 66 66 94 95 96 96 98 100 100 100 99 99 99 100 64 66 66 67 67 68
70 68 67 66 69 95 96 96 95 97 99 100 100 99 100 100 100 64 66 66 66 67 67
69 68 67 66 70 98 94 98 97 98 99 100 100 99 99 99 100 64 66 66 66 66 68
70 68 67 67 68 96 94 96 96 98 100 100 100 99 100 100 100 62 63 64 65 67 68
69 68 67 67 68 93 92 93 92 94 96 100 100 99 99 99 100 65 66 66 66 67 68
69 68 67 67 67 99 98 99 100 101 103 100 100 99 100 100 100 66 66 66 66 68 68
69 68 65 64 64 92 92 93 92 94 95 100 100 99 99 99 100 62 63 64 64 64 65
69 67 66 69 68 90 90 91 90 93 95 100 100 99 99 99 100 65 65 65 66 67 67
69 67 66 65 65 97 97 98 97 99 100 100 100 99 99 99 100 63 64 64 65 65 66
69 67 66 65 65 96 96 96 97 99 100 100 100 99 99 99 100 63 64 64 64 64 65
69 67 66 65 66 96 97 99 99 100 102 100 100 99 100 100 100 63 65 65 65 67 67
69 68 67 66 66 99 99 100 100 100 103 100 100 99 100 100 100 63 63 63 63 64 66
70 68 67 66 65 99 99 99 100 100 104 100 100 100 100 100 100 63 64 64 64 65 66
69 68 67 66 65 98 99 99 97 98 100 100 100 100 100 100 100 63 64 64 64 64 66
70 69 68 67 65 95 95 96 96 97 99 99 99 100 99 99 99 63 64 64 64 64 66
69 68 67 66 66 97 98 99 100 100 101 100 100 100 99 99 100 63 63 64 64 64 65
70 68 68 67 67 96 97 97 97 99 101 100 100 100 99 99 100 64 64 64 65 66 67
70 68 67 67 66 93 95 95 96 98 100 100 100 100 100 100 100 64 64 65 66 67 67
70 68 67 67 69 95 96 96 97 97 99 99 99 100 100 100 99 65 65 65 66 66 67
69 68 67 67 70 85 96 96 97 98 99 99 99 100 100 100 99 66 63 63 65 65 66
70 68 67 67 68 95 95 96 96 98 100 99 99 100 100 100 99 64 66 66 66 66 67
70 68 67 67 68 90 91 92 93 94 96 99 99 100 100 100 99 65 66 67 67 66 67
69 68 67 67 67 99 99 100 102 104 105 99 99 100 99 99 99 64 66 66 66 66 67
70 68 65 62 64 90 90 90 92 94 95 99 99 100 99 99 99 62 63 63 64 64 65
69 67 66 65 68 90 90 90 90 93 95 99 99 100 99 99 99 64 65 65 65 65 68
69 67 66 65 65 97 95 96 97 99 100 99 99 100 99 99 99 63 64 64 64 65 66
68 66 66 65 65 97 97 97 98 99 100 99 99 100 100 100 99 62 64 64 65 66 66
70 68 67 67 69 94 94 95 95 97 99 99 99 100 100 100 99 63 63 64 64 66 66
68 67 66 66 66 90 92 93 93 96 99 99 99 100 99 99 99 63 63 64 64 64 66
70 68 67 67 66 93 94 96 96 98 100 100 100 100 100 100 100 64 66 66 66 67 67
70 68 67 67 68 91 91 92 94 94 96 100 100 99 99 99 100 64 65 66 66 67 67
POST OPERATIVE HOURS
Group P
MAP PR SPO2 MAP
TIME TO FIRST ANALGESIC REQUIREMENT HOURS
EOS 1 2 3 4 5 6 EOS 1 2 3 4 5 6 7
3 3 2 2 1 1 1 0 0 0 1 2 3 4 5.5
3 3 2 2 1 1 1 0 0 0 0 2 3 4 5.25
3 3 2 2 1 1 1 0 0 0 1 2 3 4 5.5
3 3 2 2 1 1 1 0 0 0 1 2 3 4 6
3 3 2 2 1 1 1 0 0 0 1 2 3 4 6
3 3 2 2 1 1 1 0 0 0 1 2 3 4 6
3 3 2 2 1 1 1 0 0 0 1 2 3 4 6
3 3 2 2 1 1 1 0 0 0 1 2 3 4 5.75
3 3 2 2 1 1 1 0 0 0 1 2 3 4 5.75
3 3 2 2 1 1 1 0 0 0 1 2 3 4 6
3 3 2 1 1 1 1 0 0 0 1 2 2 4 6
3 3 2 2 1 1 1 0 0 0 1 1 2 4 6
3 3 2 2 1 1 1 0 0 0 1 1 2 3 4 7
3 3 2 2 1 1 1 0 0 0 1 1 2 3 4 7
2 2 2 1 1 1 1 0 0 0 1 1 2 3 4 6.5
3 2 2 2 1 1 1 0 0 0 1 1 2 3 4 7
3 2 2 2 1 1 1 0 0 0 1 1 2 3 4 6.5
2 2 2 2 1 1 1 0 0 0 1 1 2 3 4 6.25
3 2 2 1 1 1 1 0 0 0 1 1 2 3 4 6.25
3 2 2 2 1 1 1 0 0 0 1 1 2 3 4 7
2 2 2 2 1 1 1 0 0 0 1 1 2 3 4 6.5
3 2 2 2 1 1 1 0 0 0 1 1 2 3 4 6.5
3 2 2 2 1 1 1 0 0 0 1 1 2 3 4 7
3 2 2 2 1 1 1 0 0 0 1 2 3 4 5.5
3 3 2 2 1 1 1 0 0 0 1 2 3 4 5.25
3 2 2 2 1 1 1 0 0 0 1 2 3 4 5.5
3 3 2 1 1 1 1 0 0 0 1 2 3 4 6
3 3 2 2 1 1 1 0 0 0 1 2 3 4 6
3 3 2 1 1 1 1 0 0 0 1 2 3 4 6
3 3 2 1 1 1 1 0 0 0 1 2 3 4 6
3 3 2 1 1 1 1 0 0 0 1 2 3 4 5.75
3 2 2 1 1 1 1 0 0 0 1 1 2 3 4 7
3 3 2 2 1 1 1 0 0 0 1 2 3 4 5.5
3 2 2 1 1 1 1 0 0 0 1 1 2 3 4 5.75
3 3 2 2 1 1 1 0 0 0 1 2 3 4 6
POST OPERATIVE HOURS
Group P
SEDS VAPS
SNO NAME AGE/SEX WEIGHT PREOP DOS
P SPO2 BP JAI 5 MIN 15 MIN 30 MIN EOS JAI 5 MIN 15MIN 30MIN EOS
1 MANOJ 8/M 12KG 100 100 65 45MIN 110 107 106 105 105 100 100 99 100 100
2 KUMAR 11/M 25KG 94 100 67 45MIN 100 96 97 98 96 99 100 99 99 99
3 VALLI 14/F 25KG 90 100 67 45MIN 98 97 96 95 96 99 100 99 99 99
4 KANNAN 6/M 10KG 104 100 66 40MIN 110 108 106 104 100 100 100 99 100 100
5 MUPIDARI 12/F 25KG 90 100 66 60MIN 100 98 97 96 96 99 100 99 99 99
6 GEETHA 10/F 20KG 92 100 65 45MIN 100 98 97 96 97 100 100 99 100 100
7 PETCHI 7/M 20KG 100 100 65 50MIN 110 106 106 105 106 99 100 99 99 99
8 AYESHA 13/F 25KG 90 100 64 35MIN 100 98 97 96 100 100 100 99 100 100
9 NANDHINI 12/F 30KG 86 100 65 40MIN 96 95 93 92 96 99 100 99 99 99
10 MEENA 8/F 12KG 90 100 64 45MIN 109 107 106 105 105 100 100 99 100 100
11 KUMAR 12/M 25KG 92 100 65 45MIN 100 98 97 96 96 99 100 99 99 99
12 KRISHNAN 15/M 32KG 86 100 65 45MIN 96 94 92 90 94 99 100 99 99 99
13 RAJAKUMARI 7/F 20KG 98 100 66 45MIN 106 104 102 100 102 99 100 99 99 99
14 LAKSHMANAN 6/M 15KG 103 100 66 40MIN 107 105 102 100 102 99 100 99 99 99
15 SANTHOSH 8/M 20KG 100 100 65 40MIN 106 104 102 100 102 100 100 99 100 100
16 UYIKATTAN 7/M 20KG 100 100 66 35MIN 110 108 106 104 106 100 100 99 100 100
17 SURYA 7/M 20KG 102 100 66 40MIN 109 106 106 106 108 100 100 100 100 100
18 MERLIN 9/F 16KG 98 100 66 45MIN 107 104 103 102 104 100 100 100 100 100
19 RAJALAKSHNI 10/F 20KG 94 99 65 45MIN 106 105 104 102 105 99 99 100 99 99
20 PIRATHOSH 6/M 10KG 106 100 66 50MIN 108 107 107 106 108 99 100 100 99 99
21 SUDHA 8/F 12KG 104 100 66 40MIN 108 106 108 108 109 99 100 100 99 99
22 VALLI 11/F 25KG 94 100 66 45MIN 100 96 97 98 96 100 100 100 100 100
23 SUMATHI 14/F 30KG 90 99 65 45MIN 98 97 96 95 96 100 99 100 100 100
24 SARADHA 6/F 10KG 104 99 66 40MIN 108 106 105 104 106 100 99 100 100 100
25 ANDAL 12/F 25KG 90 99 66 60MIN 100 98 97 96 96 100 99 100 100 100
26 KUMARAN 10/M 20KG 92 99 66 45MIN 100 98 97 96 97 100 99 100 100 100
27 FAIZ 7/M 15KG 100 99 65 50MIN 110 106 106 105 106 99 99 100 99 99
28 RAJINI 13/M 25KG 90 99 66 35MIN 100 98 97 96 100 99 99 100 99 99
29 KARTHICK 12/M 30KG 86 99 64 40MIN 96 95 93 92 96 99 99 100 99 99
30 KUMAR 8/M 12KG 100 99 66 45MIN 110 107 106 105 105 99 99 100 99 99
31 SYED FATHIMA 13/F 30KG 88 99 66 40MIN 96 94 92 90 94 100 99 100 100 100
32 SARAVANAN 15/M 33KG 88 99 65 45MIN 98 97 96 95 96 100 99 100 100 100
33 RAJABHAVANI 8/F 12KG 100 99 64 35 MIN 107 104 103 102 104 99 99 100 99 99
34 LAKSHMI 10/F 18KG 96 100 65 40MIN 100 98 97 96 97 100 100 100 100 100
35 JOHN 8/M 12KG 100 100 64 45MIN 110 107 106 105 105 99 100 99 99 99
SPO2PR
INTRAOP
Group N
JAI 5 MIN 15 MIN 30 MIN EOS 1 2 3 4 5 6 1 2 3 4 5 6 1 2 3 4 5 6
69 68 67 67 69 104 105 107 108 109 110 100 100 100 99 100 100 67 68 68 69 70 70
70 66 65 67 70 95 96 97 98 99 102 99 99 100 99 99 99 66 67 67 68 69 70
70 66 66 67 70 95 96 98 99 102 103 99 99 100 99 99 99 67 68 68 69 70 72
70 68 68 67 70 99 100 104 104 105 106 100 100 100 99 100 100 67 67 67 68 69 70
70 68 67 67 70 96 96 98 99 100 102 99 99 100 99 99 99 66 68 68 70 70 70
70 68 67 67 69 96 97 99 100 101 103 100 100 100 99 100 100 69 70 70 71 72 72
69 68 67 67 69 104 106 107 109 110 111 99 99 100 99 99 99 70 70 70 71 72 72
70 68 67 67 69 99 100 102 103 104 105 100 100 100 99 100 100 68 69 69 70 71 72
70 68 67 67 69 96 96 97 99 100 102 99 99 100 99 99 99 68 68 68 69 70 70
69 68 67 67 69 103 105 107 108 109 110 100 100 100 99 100 100 67 68 68 69 70 70
70 68 66 62 67 94 96 99 100 100 102 99 99 100 99 99 99 66 66 66 66 66 68
70 69 69 69 70 93 94 95 96 97 98 99 99 100 99 99 99 68 68 68 69 69 70
69 67 66 65 69 100 102 105 106 108 108 99 99 100 99 99 99 65 66 66 67 68 68
69 67 66 65 69 100 102 105 106 107 109 99 99 100 99 99 99 67 68 68 68 69 70
69 67 66 65 69 101 103 104 106 107 107 100 100 100 99 100 100 67 68 68 69 69 70
69 68 67 66 70 106 108 108 110 110 111 100 100 100 99 100 100 66 67 67 68 69 70
69 68 67 66 70 106 113 115 117 117 118 100 100 100 100 100 100 65 67 67 67 69 71
69 68 67 66 69 104 104 106 107 110 113 100 100 100 100 100 100 65 66 66 68 68 68
69 69 68 67 70 102 105 105 107 109 110 99 99 99 100 99 99 65 66 66 68 69 69
69 68 67 66 70 108 105 106 107 108 110 99 99 100 100 99 99 66 67 67 68 69 70
69 68 67 66 70 109 104 105 106 106 107 99 99 100 100 99 99 65 66 66 67 68 69
69 66 65 67 70 95 96 97 98 99 102 100 100 100 100 100 100 66 67 67 68 69 70
69 66 66 67 70 96 96 98 99 102 103 100 100 99 100 100 100 67 68 68 69 70 71
70 68 68 67 70 106 100 104 104 105 106 100 100 99 100 100 100 67 67 67 68 69 70
70 68 67 67 70 96 96 99 99 100 102 100 100 99 100 100 100 66 68 68 70 70 70
70 68 67 67 69 97 98 100 100 101 103 100 100 99 100 100 100 69 70 70 70 71 72
69 68 67 67 69 106 99 100 102 104 105 99 99 99 100 99 99 68 69 69 70 71 71
70 68 67 67 70 100 100 102 103 104 105 99 99 99 100 99 99 68 69 69 70 71 72
70 68 67 67 70 96 96 97 99 100 102 99 99 99 100 99 99 68 68 68 69 70 70
69 68 67 67 70 105 100 102 104 105 105 99 99 99 100 99 99 67 68 68 69 70 70
73 72 70 69 70 94 94 95 97 99 100 100 100 99 100 100 100 68 68 68 69 69 70
70 66 66 67 70 96 96 98 99 102 103 100 100 99 100 100 100 67 68 68 69 70 72
69 68 67 66 69 104 102 103 104 105 106 99 99 99 100 99 99 65 66 66 68 68 70
70 68 67 67 70 97 97 99 100 101 103 100 100 100 100 100 100 69 70 70 71 72 72
69 68 67 67 70 105 103 104 104 105 106 99 99 100 99 99 99 67 68 68 69 70 70
SPO2PRMAP
Group N
INTRAOP POST OPERATIVE HOURS
MAP
EOS 1 2 3 4 5 6 EOS 1 2 3 4 5 6 7
2 1 1 1 1 1 1 1 2 2 4 2.25
1 1 1 1 1 1 1 1 1 2 4 2.5
2 1 1 1 1 1 1 1 2 2 4 2.5
2 1 1 1 1 1 1 1 2 3 4 2.25
2 1 1 1 1 1 1 1 1 2 4 2.5
2 1 1 1 1 1 1 1 2 2 4 2.25
2 1 1 1 1 1 1 1 2 2 4 3
2 1 1 1 1 1 1 1 1 2 4 3
2 1 1 1 1 1 1 1 2 2 4 2.75
2 1 1 1 1 1 1 1 2 2 4 2.5
2 1 1 1 1 1 1 1 1 2 4 2.5
2 1 1 1 1 1 1 1 2 2 4 2.25
2 1 1 1 1 1 1 1 2 3 4 3
2 1 1 1 1 1 1 1 1 2 4 3
2 1 1 1 1 1 1 1 2 3 4 3
2 1 1 1 1 1 1 1 2 2 4 3
2 1 1 1 1 1 1 1 2 2 4 3
1 1 1 1 1 1 1 1 1 3 4 3
2 1 1 1 1 1 1 1 2 2 4 2.25
2 1 1 1 1 1 1 1 3 2 4 2.25
2 1 1 1 1 1 1 1 2 2 4 2.5
2 1 1 1 1 1 1 1 1 2 4 2.5
2 1 1 1 1 1 1 1 2 3 4 2.5
2 1 1 1 1 1 1 1 2 2 4 3
2 1 1 1 1 1 1 1 1 2 4 3
2 1 1 1 1 1 1 1 2 3 4 3
2 1 1 1 1 1 1 1 2 2 4 3
2 1 1 1 1 1 1 1 1 3 4 2.25
2 1 1 1 1 1 1 1 2 2 4 2.25
2 1 1 1 1 1 1 1 2 2 3 2.5
2 1 1 1 1 1 1 1 2 2 4 2.5
2 1 1 1 1 1 1 1 2 3 4 2.5
2 1 1 1 1 1 1 1 1 2 4 2.25
2 1 1 1 1 1 1 1 2 2 4 2.5
2 1 1 1 1 1 1 1 2 3 4 3
TIME TO FIRST ANALGESIC 
REQUIREMENT Hours
Group N
POST OPERATIVE HOURS
SEDS VAPS
